Breaking News

Evotec Earns Roche Milestone in Biomarker Pact

April 24, 2014

Phase I trial to employ prediction marker using Evotec's Proteome platform

Evotec AG has achieved a milestone in its biomarker alliance with Roche. Roche will use a response prediction marker, identified using Evotec's Proteome Profiling platform, in an extended Phase I oncology trial.
 
This is the first milestone achieved under the collaboration and license agreement signed in 2011. Under the initial three-year term, Evotec and Roche conduct biomarker discovery and validation programs for patient stratification in targeted cancer therapy. Evotec is eligible for further success-based payments upon clinical companion diagnostics development.
 
Dr. Mario Polywka, chief operating officer of Evotec AG, said, "We are delighted with receiving this milestone and the first validation of our novel biomarker concept with Roche. I would like to thank everyone involved in the project to date for the fantastic science they have developed and for the hard work and determination to see it succeed in a clinical setting."

Related Contract Manufacturing:

Related Compliance:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers